Beyond anti-PCSK9 therapies: The potential role of resistin inhibitors

Nature Reviews Cardiology

Volumn 11, Issue 1, 2014, Pages 12-

  Sahebkar, Amirhossein ^a  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ALIROCUMAB; EVOLOCUMAB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; RESISTIN; RESISTIN INHIBITOR; SERINE PROTEINASE; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; UNCLASSIFIED DRUG;

DRUG EFFICACY; DRUG MECHANISM; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; LETTER; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; AZETIDINES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; PROPROTEIN CONVERTASES;

EID: 84891143050     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2013.139-c1     Document Type: Letter

References (12)

1. Davidson, M. H. PCSK9 antibodies: a dividend of the genomics revolution. Nat. Rev. Cardiol. 10, 618-619 (2013).
2. Sullivan, D. et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 308, 2497-2506 (2012).
3. Raal, F. et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial. Circulation 126, 2408-2417 (2012).
4. McKenney, J. et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J. Am. Coll. Cardiol. 59, 2344-2353 (2012).
5. Roth, E. M. et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N. Engl. J. Med. 367, 1891-1900 (2012).
6. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01663402 (2013).
7. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01764633 (2013).
8. Dias, C. et al. Effects of AMG 145, a fully human monoclonal antibody against PCSK9, on low-density lipoprotein cholesterol in subjects taking statins: a phase I, randomized, double-blind, placebo-controlled, ascending multiple-dose study [abstract 923-4]. J. Am. Coll. Cardiol. 59, E1379 (2012).
9. Stein, E. A. et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N. Engl. J. Med. 366, 1108-1118 (2012).
10. Melone, M., Wilsie, L., Palyha, O., Strack, A. & Rashid, S. Discovery of a new role of human resistin in hepatocyte low-density lipoprotein receptor suppression mediated in part by proprotein convertase subtilisin/kexin type 9. J. Am. Coll. Cardiol. 59, 1697-1705 (2012).
11. Hampton, E. N. et al. The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain. Proc. Natl Acad. Sci. USA 104, 14604-14609 (2007). (Pubitemid 350003191)
12. Jamaluddin, M. S. et al. Resistin: functional roles and therapeutic considerations for cardiovascular disease. Br. J. Pharmacol. 165, 622-632 (2012).